AbCellera on X

We discover & develop antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune ...

AbCellera: Home

AbCellera will be presenting a poster: Development of PSMA x CD3 T-cell engagers using an integrated, functional approach at Antibody Engineering ...

AbCellera and Lilly Expand Collaboration to Develop Antibody ...

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines https://t.co/nrxQcIPwaH.

AbCellera on X: "Learn about how novel CD3-binding antibodies ...

Learn about how novel CD3-binding antibodies could widen the therapeutic window for T-cell engagers by visiting our poster at Festival of ...

AbCellera - X.com

Congratulations to our partner, @AbderaTx, on receiving FDA clearance for its IND application for ABD-147, an antibody-based precision ...

News - AbCellera

Development of PSMA x CD3 T-cell engagers using an integrated, functional approach (Abstract #6359). See the press release. Apr 15-17, 2024. Festival of ...

AbCellera and Lilly Expand Collaboration to Develop Antibody ...

AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to discover ...

AbCellera Announces Four Presentations on T-Cell Engagers at ...

AbCellera (Nasdaq: ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and ...

AbCellera Biologics, Inc. - Drug pipelines, Patents, Clinical trials

... Drug:ABCL-635, Precision ADCs(Prelude Therapeutics/AbCellera Biologics), MAGE-A4 pMHC T cell engager(AbCellera), CD3 x PSMA TCE(AbCellera), SP34-2.

Buy AbCellera Biologics Stock - ABCL Stock Price Today & News

$0.00 (0.00%). Current ratio. 9.34x. Next earnings, 02/18/2025. AbCellera Biologics Stock Rating. What analysts recommend for ABCL stock, on a scale from 1(buy) ...

AbCellera to Present at Upcoming Investor Conferences in September

About AbCellera Biologics Inc . AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, ...

AbCellera Biologics Inc. - AnnualReports.com

AbCellera Biologics Inc. 2021 Annual Report View Annual Report Download. AbCellera Biologics Inc. 2020 Annual Report View Annual Report Download. x. AbCellera ...

AbCellera and Lilly broadens antibody discovery partnership

AbCellera is entitled to research payments and downstream milestone payments from Lilly. August 1, 2024. Share. Copy Link · Share on X · Share on Linkedin ...

AbCellera Biologics company information, funding & investors

AbCellera Biologics, innovator in antibody discovery for therapeutics, and immune profiling for vaccine research ... 00.0x, 00.0x, 00.0x, 00.0x, 00.0x, 00.0x ...

ABCL | AbCellera Biologics Inc. Stock Overview (U.S.: Nasdaq)

Complete AbCellera Biologics Inc. stock information by Barron's. View ... The chart has 1 X axis displaying Time. Range: 2024-11-13 09:23:42 to 2024 ...

AbCellera Biologics Inc. (ABCL) Stock Price, Quote, News & Analysis

View as data table, AbCellera Biologics Inc. price and volume. The chart has 2 X axes displaying Time, and Time. The chart has 2 Y axes ...

ABCL EV/EBITDA | Abcellera Biologics Inc (ABCL) - ValueInvesting.io

Note: valuation result may not be accurate due to the company's negative EBITDA. Range, Selected. Trailing EV/EBITDA multiples, 11.6x - 13.6x, 12.2x.

Why AbCellera Biologics Is Still A Buy Despite Dropping Royalties

Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification. Markets · Bonds · Funds · Pre-Market ...

abcellera biologics inc. (abcl) - MSN Money

0 55.0x 110.0x 215.7x ABCL REGN VRTX ALNY ARGX 23.23x 9.26x 12.35x 14.71x 15.28x Peer Avg ‎11.35x Industry Avg ‎215.68x. ABCL is trading at a P/S multiple ...

AbCellera Biologics Inc. Common Shares (ABCL) - Nasdaq

AbCellera Biologics Inc. Common Shares (ABCL). Bid: $3.00 X 1375.0. Ask: $3.01 X 1177.0. Volume: 612,828. 52 Week Range: 2.34 - 6.06. High/Low: 2.99 - 3.09.